Former FDA AI regulator says biopharma is misreading guidance

Tala Fakhouri, former FDA AI policy writer now at Parexel, says the biopharma industry is overly cautious and misinterpreting FDA's guidance on AI in drug development. She urges a more balanced approach to avoid stifling innovation.

Featured · Tala Fakhouri